Lucid Genomics GmbH

Based in Germany, Lucid Genomics GmbH is a healthcare technology company that specializes in advanced genomic analysis, transforming complex data into actionable genetic insights to support research and clinical diagnostics. Lucid Genomics GmbH, founded in 2024 in Berlin, Germany, focuses on genomic analysis through its innovative software. The company was established by M. Hossein Moeinzadeh, Tessa Remmers, Uirá Melo, and is currently led by CEO Uirá Melo.

In August 2024, they completed a funding round raising EUR 1. 3 million led by Caesar Ventures, with contributions from BIF Partners, Max Planck Foundation, and another. vc. The total amount raised to date is EUR 1.

3 million, valuing the company at EUR 6. 746 million. Lucid Genomics specializes in advanced genomic analysis through its innovative software platform designed to transform noisy data from whole genome sequencing into actionable insights. Their core offerings focus on comprehensive genome analysis and mutation detection, prioritization, and interpretation, catering to various users including research institutions, pharmaceutical companies, and clinical diagnostics labs.

The software analyzes genetic data at the cohort, family, or individual level, yielding a refined list of potentially pathogenic mutations while significantly reducing false positives in structural variant detection by up to 87%. The company serves a diverse global market, with applications in drug discovery, personalized medicine, and clinical research, addressing critical challenges in genetic diagnostics and therapeutic development. Lucid Genomics operates on a subscription-based revenue model that supports its clients in accessing its advanced genomic analysis tools. Transactions typically take place through direct partnerships with research organizations and healthcare providers, facilitating a streamlined integration of their software solutions.

The pricing structure encompasses tiered subscription plans which provide varying levels of access to the platform's features, enhancing flexibility for users based on their specific needs. Flagship products such as the Lucid Genome Suite are central to their offerings, delivering high-quality genomic insights tailored to the demands of their clientele. The company is positioned to leverage its technology to create sustainable revenue streams while impacting the efficiency and accuracy of genomic research and diagnostics. In August 2024, Lucid Genomics GmbH raised EUR 1.

3 million in pre-seed funding led by Caesar Ventures, which will be utilized to enhance the capabilities of their genomic analysis platform. The company is in the process of developing new products aimed at expanding their market presence, particularly targeting the research and clinical diagnostics sectors in Europe and North America by mid-2025.